News | August 11, 2022
IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Subscribe To Our Newsletter & Stay Updated
